QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)

Cerus Stock Price, News & Analysis (NASDAQ:CERS)

$1.65
+0.03 (+1.85%)
(As of 12/7/2023 ET)
Compare
Today's Range
$1.59
$1.68
50-Day Range
$1.25
$1.79
52-Week Range
$1.21
$4.25
Volume
997,929 shs
Average Volume
1.33 million shs
Market Capitalization
$298.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.38

Cerus MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
104.5% Upside
$3.38 Price Target
Short Interest
Healthy
3.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.22) to ($0.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

769th out of 960 stocks

Surgical & Medical Instruments Industry

66th out of 75 stocks


CERS stock logo

About Cerus Stock (NASDAQ:CERS)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

CERS Stock Price History

CERS Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Cerus: Q2 Earnings Snapshot
Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates
Cerus Corporation Common Stock (CERS)
Cerus bags additional $8.7M contract amendment
See More Headlines
Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:CERS
CUSIP
15708510
Employees
665
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$3.38
High Stock Price Target
$3.75
Low Stock Price Target
$3.00
Potential Upside/Downside
+105.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-42,780,000.00
Pretax Margin
-32.13%

Debt

Sales & Book Value

Annual Sales
$153.63 million
Book Value
$0.39 per share

Miscellaneous

Free Float
168,423,000
Market Cap
$297.16 million
Optionable
Optionable
Beta
1.20

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report














CERS Stock Analysis - Frequently Asked Questions

Should I buy or sell Cerus stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares.
View CERS analyst ratings
or view top-rated stocks.

What is Cerus' stock price target for 2024?

3 brokers have issued 12 month price objectives for Cerus' shares. Their CERS share price targets range from $3.00 to $3.75. On average, they predict the company's stock price to reach $3.38 in the next year. This suggests a possible upside of 104.5% from the stock's current price.
View analysts price targets for CERS
or view top-rated stocks among Wall Street analysts.

How have CERS shares performed in 2023?

Cerus' stock was trading at $3.65 at the beginning of the year. Since then, CERS shares have decreased by 54.8% and is now trading at $1.65.
View the best growth stocks for 2023 here
.

When is Cerus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CERS earnings forecast
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) released its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.02. The biotechnology company had revenue of $39.77 million for the quarter, compared to analyst estimates of $40.90 million. Cerus had a negative net margin of 32.40% and a negative trailing twelve-month return on equity of 84.23%.

What ETFs hold Cerus' stock?

ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ARK Innovation ETF (ARKK).

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.10%), Sumitomo Mitsui Trust Holdings Inc. (4.38%), Senvest Management LLC (4.01%), Sepio Capital LP (1.93%), Northern Trust Corp (1.02%) and Walleye Capital LLC (1.00%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends
.

How do I buy shares of Cerus?

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CERS) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -